诺和诺德股价下跌，摩根士丹利质疑其抵消潜力
· gurufocus.com
诺和诺德（NVO）盘前下跌1.23%，此前摩根士丹利将其评级从平配下调至低配，维持250丹麦克朗的目标价，意味着超过10%的下行空间。
Novo Nordisk NVO fell 1.23% premarket after Morgan Stanley downgraded it to Underweight from Equal-weight, keeping a 250 DKK target that implies more than 10% d...